Are Dopamine or Norepinephrine PET Scans Used Clinically in ADHD? 

PET scans (Positron Emission Tomography) are a type of functional imaging that can measure the activity of neurotransmitters like dopamine and norepinephrine in the brain. These scans hold significant promise for understanding the neurobiology of ADHD, as they provide real-time data on how these neurotransmitters function in key brain regions involved in attention, reward, and impulse control. However, despite their potential, dopamine and norepinephrine PET scans are not commonly used in routine clinical practice for diagnosing ADHD. 

PET Scans and Their Role in ADHD Research 

In ADHD research, PET scans are often used to study dopamine and norepinephrine dysfunction by looking at the density and activity of dopamine transporters (DAT) and norepinephrine transporters (NET). These scans can reveal areas of the brain with abnormal neurotransmitter function, such as reduced dopamine availability in the prefrontal cortex or dysregulated norepinephrine levels in areas that control attention and emotional responses. The information gleaned from PET scans has contributed to our understanding of ADHD’s neurobiological underpinnings. 

Clinical Application of PET Scans in ADHD 

While PET scans provide valuable insights into dopamine and norepinephrine imbalances in ADHD, they are not yet routinely used in clinical settings for diagnosis. The high cost, limited availability, and the need for specialised equipment and expertise make PET scans less practical for widespread clinical use. Instead, ADHD is primarily diagnosed through behavioural assessments and neuropsychological tests. 

In summary, while dopamine and norepinephrine PET scans are valuable tools in ADHD research, they are not currently a standard part of ADHD diagnosis in clinical practice. 

Visit providers like ADHD Certify for personal consultations to explore how PET scans can enhance our understanding of dopamine and norepinephrine function in ADHD.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Dopamine and norepinephrine systems.

Victoria Rowe, MSc

Author

Victoria Rowe is a health psychologist with a Master’s in Health Psychology and a BS in Applied Psychology. She has experience as a school psychologist, conducting behavioural assessments, developing individualized education plans (IEPs), and supporting children’s mental health. Dr. Rowe has contributed to peer-reviewed research on mental health, including studies on anxiety disorders and the impact of COVID-19 on healthcare systems. Skilled in SPSS, Minitab, and academic writing, she is committed to advancing psychological knowledge and promoting well-being through evidence-based practice.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Rebecca Fernandez, MBBS

Reviewer

Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence-based approaches such as CBT, ACT, and mindfulness-based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewer's privacy.